bimatoprost
Latisse · Lumigan
1 INDICATIONS AND USAGE Bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )
Mechanism. 12.1 Mechanism of Action Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
What stands out in the reports.
ROR = reporting odds ratio (log-schaal). Een waarde boven 1 betekent dat het symptoom vaker wordt gemeld voor dit product dan voor alle andere producten samen. Dit meet hoeveel het opvalt in meldingen — geen causaliteit, geen risico.
Le bimatoprost montre des signaux disproportionnés pour la pigmentation palpébrale (ROR 904.1) et la croissance des cils (ROR 441.6). Ces effets sont logiques, car le bimatoprost est un analogue des prostaglandines connu pour stimuler la croissance des cils et potentiellement modifier la pigmentation. L'augmentation de la lacrymation (ROR 9.6) et la trichorrhexis (ROR 83.2) sont également disproportionnellement notifiées. **Fréquemment notifié n'est pas synonyme de fréquemment causé.** Ceci ne remplace pas un avis médical.
Dit vervangt geen medisch advies.
No signals currently mapped to the label.
Report volume per quarter.
| Date | Class | Reason | Firm |
|---|---|---|---|
| Oct 19, 2017 | III | Failed Impurities/Degradation Specifications. | Allergan Sales, LLC |
| Mar 16, 2017 | III | Failed Impurities/Degradation Specifications | Allergan Sales, LLC |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm. Source: openFDA enforcement.